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Purpose: The objective of this study is to investigate and analyze the epidemiologic 
characteristics and time trends of ovarian cancer incidence and mortality in Jiangsu 
Province of China during 2003–2012.
Method: Data were collected from eligible cancer registries in Jiangsu Province. 
Crude rates, age-specific rates, truncated age-standardized rate, and proportions of 
ovarian cancer were calculated. The Segi’s World Population was used to calculate 
age- standardized rates for world (ASW). Poisson distribution was used to analyze the 
differences between urban and rural areas. Joinpoint regression was performed to esti-
mate the annual percent change (APC) of ovarian cancer incidence/mortality.
results: A total number of 4,401 new cases and 1,918 deaths were identified 
during period 2003–2012. The incidence and mortality ASW was 3.64/100,000 and 
1.52/100,000, respectively. ASW of incidence was 4.48/100,000 in urban areas, while 
3.04/100,000 in rural areas. The mortality of ASW was slight higher in urban areas than 
in rural areas. Age-specific incidence showed a peak at the age group of 60–64 years, 
whereas mortality peaked at age group of 65–69 years. A significant increase of inci-
dence was observed from 2003 to 2006, with an APC of 34.0% (95% CI: 9.7, 63.7), the 
increasing rate declined since 2006 (APC = 3.3%, 95% CI: −3.5, 10.5). The mortality 
showed a gentle upward trend as compared with incidence, with an APC of 9.9% 
(95% CI: 7.7, 12.2) per year, continuously from 2003 to 2012. It is apparent that both 
incidence and mortality presented a rising trend in all areas, but urban were higher than 
that in rural areas.
conclusion: Ovarian cancer is a highly lethal disease which is becoming a significant 
public health problem in Chinese women. It is vital to improve the understanding of 
current status of ovarian cancer. Moreover, prevention and control policies should be 
formulated to reduce the disease burden of ovarian cancer in China.
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inTrODUcTiOn
Ovarian cancer is the sixth most common malignancy cancer in 
the world (1). It is one of the three major types of gynecological 
malignancy and ranks third after cervical cancer and uterine 
corpus cancer. Although the incidence and mortality of ovarian 
cancer are not very high as compared with common cancers, 
the absence of either specific symptoms or effective screening 
strategies caused more than 70% of patients were in advanced 
stage when diagnosed (2), which results in relatively high risk 
of recurrence and poor prognosis. According to report of Beard 
et al. (3), the relative 5-year survival rate for stage I ovarian cancer 
was 81%, however, for stage II, III, and IV was only about 59, 30, 
and 20%, respectively (3).
Ovarian cancer incidence has been rising continuously in the 
world, with 200,000 new cases diagnosed every year. International 
Agency for Research on Cancer (IARC) estimated that the world 
new cases and deaths of ovarian cancer were 238,700 and 151,900 
occurred in 2012 worldwide, which accounted for 3.59 and 4.28% 
of all malignant cancer among women (4), and the number was 
higher than that in 2008, which was 225,000 cases and 140,000 
deaths, respectively (5).
Similar as many common cancers, the risk of ovarian cancer 
varies across the world. Generally, higher incidence was observed 
in developed counties such as Northern Europe (11.3/100,000) 
and Northern America (10.7/100,000), while China (3.2/100,000) 
has been found with the lower incidence (6). But in recent years, 
the incidence of ovarian cancer in China showed an upward trend 
(7). However, few data have reported the situation of ovarian 
cancer in China.
Jiangsu Province is one of the developed areas and located 
in South-Eastern part of China. The population of Jiangsu is 
more than 80 million and 49.96% of which are women. With a 
large number population of women, gynecologic malignancy 
worth more public attention. Besides, Jiangsu is a high cancer 
risk area, according to the results of the 1990–1992 National 
Mortality Retrospective Sampling Survey, cancer mortality was 
159.8/100,000 in Jiangsu and was about 50% higher than the 
national average (108.3/100,000) (8). Some papers have described 
the epidemiology of uterine corpus cancer and breast cancer, 
whereas no previous reported the incidence and mortality of 
ovarian cancer in Jiangsu Province yet.
The purpose of this study is to analyze and describe the epi-
demiologic characteristics and time trends of ovarian cancer in 
Jiangsu Province. It aims to improve the understanding of current 
status of ovarian cancer and to provide more scientific basis for 
the prevention of this disease in China.
MaTerials anD MeThODs
Data collection
The data of ovarian cancer during 2003–2012 were collected 
from the Jiangsu Provincial Cancer Registry. Jiangsu Provincial 
Cancer Registry is responsible for organizing, administrating, 
and supervising cancer registry works in different counties in the 
province. Cancer registry was first initiated in 1970s in several 
counties (9) and has been developed dramatically over the past 
years, now the registry system has covered the whole province. 
In our study, only 7 counties could provide integrated data since 
2003, while eligible cancer registry areas gradually reached to 32 
counties in 2012. Information of ovarian cancer patients, includ-
ing personal information (name, age, birth date, phone number, 
address, etc.) and diagnostic information (onset date, diagnostic 
basis, etc.), were collected using standardized cancer registry 
card. From 2003 to 2012, the total population obtained in select 
registry areas was 176,104,111 person years (women accounted 
for almost 50%), which included urban and rural population of 
73,955,792 and 102,148,319, respectively.
Quality control
Based on the protocol of assessment and recruitment criteria of 
data quality from the National Central Cancer Registry of China 
(NCCR), the MS-FoxPro, MS-Excel, and IARC-crg Tool were 
used for quality evaluation and data cleaning. Indices of reliability, 
validity, and integrity were checked by using the proportion of 
morphological verification (MV%), percentage of cancer cases 
identified with death certification only (DCO%), mortality to 
incidence ratio (M/I), and percentage of unknown basis of diag-
nosis (UB%) (10). In our research, the MV% of ovarian cancer was 
77.54%, DCO% was 0.64%, UB% was 0.27%, and M/I was 0.44, 
which indicated that the quality of data was at reasonable level.
statistical analyses
The 10th version of International Classification of Diseases (ICD-
10) was used for case identification; the code for ovarian cancer 
is C56. We calculated the crude rate and age-specific rate (0–, 
1–4, 5–84 sub-stratified by 5, and 85+ years) using the number of 
new cases/deaths divided by women population in registry areas 
during the same period. The Fifth Chinese National Population 
Census in 2000 and Segi’s World Population were used to calcu-
late age-standardized rates for China (ASR) and world (ASW) 
(11). The truncated age-standardized rate (TASR) was calculated 
among 35–64 age group using world standard population. Poisson 
distribution was used to analyze the differences between urban 
and rural areas. The annual percent change (APC) was applied to 
describe the time trends of incidence and mortality from 2003 to 
2012. Joinpoint regression software (Version 4.3.1.0) was used to 
identify significant changes and trends in ovarian cancer, which 
is available through the surveillance research program of the US 
National Cancer Institute (12). Analysis started with 0 and tested 
by fitting model with a maximum of 1 joinpoint. The slope of each 
line segment of the best-fitting model was expressed as the APC 
in the crude and ASW rate.
resUlTs
It could be observed in Table 1 that a total number of 4,401 new 
cases were identified in selected cancer registry areas within the 
period of 2003–2012, which accounted for 2.27% and ranked 11 
of all malignancy cancers among female. The crude and ASW 
incidence was 5.03/100,000 and 3.64/100,000, respectively. For 
people aged 35–64  years, the TASR was 7.82/100,000. It could 
also be seen in Table 1 that the crude rate, ASW, and the TASR in 
urban areas were higher than in rural areas.
Table 1 | The incidence and mortality of ovarian cancer in Jiangsu, 2003–2012.
index Women 
population
new cases 
/deaths
crude  
rate (1/105)
asr  
(1/105)
asW  
(1/105)
cumulative rate (%) Tasr (1/105) 
35–64
Proportion  
(%)
rank
0–64 0–74
Incidence All 87,567,627 4,401 5.03 3.82 3.64 0.28 0.39 7.82 2.27 11
Urban 50,779,425 2,249 6.11 4.70 4.48 0.34 0.47 9.34 2.61 10
Rural 36,788,202 2,152 4.24 3.18 3.04 0.24 0.33 6.74 2.01 11
Mortality All 87,567,627 1,918 2.19 1.54 1.52 0.11 0.18 3.17 1.56 14
Urban 50,779,425 889 2.42 1.70 1.68 0.11 0.19 3.32 1.81 13
Rural 36,788,202 1,029 2.03 1.43 1.42 0.11 0.17 3.06 1.40 14
Table 2 | age-specific incidence and mortality of ovarian cancer in Jiangsu, 2003–2012.
age group incidence Mortality
all Urban rural all Urban rural
cases rate  
(1/105)
cases rate  
(1/105)
cases rate  
(1/105)
Deaths rate  
(1/105)
Deaths rate  
(1/105)
Deaths rate  
(1/105)
0~ 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00
1~ 1 0.03 1 0.09 0 0.00 0 0.00 0 0.00 0 0.00
5~ 2 0.05 1 0.06 1 0.04 0 0.00 0 0.00 0 0.00
10~ 10 0.19 2 0.09 8 0.27 2 0.04 0 0.00 2 0.07
15~ 43 0.76 23 0.95 20 0.61 9 0.16 2 0.08 7 0.21
20~ 99 1.55 58 2.06 41 1.15 15 0.24 7 0.25 8 0.22
25~ 123 1.86 78 2.60 45 1.25 25 0.38 10 0.33 15 0.42
30~ 138 1.86 85 2.63 53 1.26 19 0.26 9 0.28 10 0.24
35~ 213 2.79 111 3.49 102 2.29 43 0.56 20 0.63 23 0.52
40~ 444 5.70 231 7.11 213 4.70 119 1.53 55 1.69 64 1.41
45~ 595 8.32 288 9.79 307 7.29 211 2.95 93 3.16 118 2.80
50~ 562 9.53 270 11.23 292 8.36 242 4.10 95 3.95 147 4.21
55~ 648 12.14 308 13.72 340 10.99 283 5.30 123 5.48 160 5.17
60~ 511 12.19 268 15.05 243 10.08 276 6.58 126 7.08 150 6.22
65~ 390 11.50 193 14.15 197 9.72 243 7.17 116 8.51 127 6.27
70~ 269 9.72 129 11.77 140 8.38 167 6.04 78 7.12 89 5.33
75~ 184 8.74 90 10.66 94 7.45 132 6.27 73 8.64 59 4.68
80~ 91 6.82 51 9.51 40 5.02 86 6.45 51 9.51 35 4.39
85~ 78 9.13 62 17.92 16 3.15 46 5.39 31 8.96 15 2.95
2003–2012 4,401 5.03 2,249 6.11 2,152 4.24 1,918 2.19 889 2.42 1,029 2.03
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The number of deaths (1,918) accounted for 1.56% of total 
female malignancies from 2003 to 2012. The crude mortality 
rate was 2.19/100,000, higher than ASW (1.52/100,000). Even 
though the mortality difference between urban and rural areas 
was less obvious than incidence, the various indicators showed 
that mortality in urban areas were slight higher than rural area.
The age-specific incidence and mortality of ovarian cancer 
during the period of 2003–2012 in Jiangsu were presented in 
Table 2 (Figures 1 and 2). The ovarian cancer incidence was rela-
tively lower before 40 years old, but increased rapidly after then 
and first peaked at the age group of 60–64 years (12.19/100,000). 
Afterward, the rate dramatically decreased to 6.82/100,000 at the 
age group of 80–84 years, but then increased again among women 
aged 85 years or older. The pattern was similar between urban and 
rural areas. But, the age-specific incidence was higher in urban 
area than in rural area. And, there was only one peak in rural 
area at the age group of 55–59 years. The trend of age-specific 
mortality was similar to its age-specific incidence, which also had 
two peaks. One peak was at the age group of 65–69  years and 
the second at age of 80–84. Similar patterns were found both in 
urban and rural areas. But only one peak was found in rural area. 
Comparing the rural area, the age-specific mortality in urban area 
was higher in most of age groups.
Results of joinpoint regression analysis are presented in 
Table  3. Year 2006 was chosen as a jointpoint to separate the 
trend. A significant increase of incidence was observed from 2003 
to 2006, with an APC of 34.0% (95% CI: 9.7, 63.7). However, the 
increasing rate declined since 2006 (APC = 3.3%, 95% CI: −3.5, 
10.5). The mortality showed a gentle upward trend as compared 
with incidence, with an APC of 9.9% (95% CI: 7.7, 12.2). The 
temporal time trend for ASW incidence was similar to crude 
rate. But, the ASW for mortality was significantly increased by 
7.2% (95% CI: 5.2, 9.2) per year, continuously from 2003 to 2012. 
The APC in urban areas was higher than that in rural areas for 
both incidence and mortality during the period of 2003–2012 
(Figures 3 and 4). After age standardizing adjustment for Segi’s 
World Population, the APC of incidence and mortality became 
smaller in both urban and rural areas, but still with increasing 
trends. Moreover, the increasing trends of crude and ASW showed 
statistically significant except ASW mortality in rural areas.
FigUre 2 | age-specific mortality of ovarian cancer in Jiangsu, 2003–2012.
FigUre 1 | age-specific incidence of ovarian cancer in Jiangsu, 2003–2012.
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DiscUssiOn
Ovarian cancer is one of the most lethal gynecological malignan-
cies. The exact etiology of ovarian cancer is still unclear, but it 
has been correlated with obesity, diet, lifestyle, environment, 
socioeconomic status, reproductive history, oral contraceptive, 
family history, and genetic factors (13).
Similar to many other types of cancer, there is significant geo-
graphic disparity in ovarian cancer incidence and mortality (14). 
According to the GLOBOCAN 2012 database, the incidence and 
Table 3 | The annual incidence and mortality and time trends for ovarian cancer in Jiangsu, 2003–2012.
index area 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Trend 1 Trend 2 Total 
aPc
Period aPc%  
(95% ci)
Period aPc%  
(95% ci)
incidence
Crude rate 
(1/105)
All 1.83 3.05 3.14 4.63 4.89 5.56 5.16 4.81 5.54 5.90 03–06 34.0a  
(9.7, 63.7)
06–12 3.3  
(−3.5, 10.5)
11.1
Urban 1.20 0.52 2.08 5.28 6.65 7.29 6.05 5.91 6.09 7.07 03–12 26.6a  
(8.6, 47.6)
26.6
Rural 1.99 3.55 3.35 3.83 4.06 3.98 4.71 3.82 4.96 5.02 03–12 7.5a  
(3.2, 12)
7.5
P 0.15 <0.01 0.06 0.01 <0.01 <0.01 0.02 <0.01 0.02 <0.01
ASW  
(1/105)
All 1.46 2.41 2.41 3.41 3.90 3.91 3.77 3.45 4.04 4.03 03–06 31.6a  
(8.1, 60.3)
06–12 1.9  
(−4.7, 8.9)
9.4
Urban 1.02 0.51 1.98 3.84 5.19 4.91 4.64 4.51 4.51 4.88 03–07 67.4a  
(4.4, 168.4)
07–12 −2.2  
(−29.9, 36.6)
22.9
Rural 1.55 2.73 2.48 2.89 3.29 2.95 3.34 2.58 3.55 3.40 03–12 5.9a  
(1.2, 10.8)
5.9
P 0.23 <0.01 0.42 0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01
Mortality
Crude rate 
(1/105)
All 1.14 1.19 1.70 1.71 1.68 1.97 2.28 2.32 2.50 2.71 03–12 9.9a  
(7.7, 12.2)
9.9
Urban 0.17 0.35 0.69 1.36 2.07 2.36 2.27 2.92 2.58 2.94 03–07 87.6a  
(73, 103.4)
07–12 4.8  
(−1.0, 11)
34.2
Rural 1.38 1.35 1.90 2.14 1.49 1.62 2.29 1.77 2.41 2.53 03–12 5.9a  
(1.6, 10.4)
5.9
P <0.01 <0.01 <0.01 0.02 0.13 0.01 0.95 <0.01 0.49 0.10
ASW  
(1/105)
All 0.90 0.99 1.31 1.25 1.29 1.35 1.59 1.62 1.70 1.73 03–12 7.2a  
(5.2, 9.2)
7.2
Urban 0.12 0.33 0.66 0.97 1.58 1.51 1.64 2.15 1.80 1.83 03–06 111.5a  
(72, 160)
06–12 8.2a  
(0.9, 16.0)
30.4
Rural 1.06 1.12 1.41 1.61 1.16 1.18 1.57 1.21 1.60 1.66 03–12 3.5  
(−0.3, 7.5)
3.5
P <0.01 <0.01 0.05 <0.01 0.14 0.10 0.78 <0.01 0.23 0.27
aThe annual percent change (APC) is statistically significantly at alpha = 0.05; p < 0.05 means statistically significant.
5
Teng et al. Ovarian Cancer Incidence and Mortality
Frontiers in Public Health | www.frontiersin.org July 2016 | Volume 4 | Article 146
mortality in developed areas was 9.1/100,000 and 5.0/100,000, 
respectively, which was higher than those in less developed areas 
(5.0/100,000 and 3.1/100,000) (4). Higher incidence areas were 
observed in Europe, North America, and lower in Asia, Brazil, 
Mexico, with approximately four times between the highest and 
the lowest incidence regions; besides, the mortality was over three 
times between the corresponding areas (14–16).
Similar variations have been described between different races 
by other studies (17). Morris et  al. (18) reported that ovarian 
cancer incidence was higher in White (12.8/100,000) than Black 
(9.8/100,000) women (18). While compared with White, the Africa-
American women were more likely to have higher mortality, due 
to the lack of sufficient diagnostics and sophisticated treatments, 
which usually led to presents more advanced cancers and shorter 
disease-free survival (19–22). The disparity of ovarian cancer in 
different world regions and races suggested that genetic factors and 
environmental factors, such as socioeconomic conditions, lifestyle, 
and other risk factors, may ultimately determine the risks (2).
China is one of the developing countries with the lowest inci-
dence and mortality among selected areas (23), but an upward 
trend was observed from 2003 to 2007 (24). In this study, APC in 
2006–2012 (APC = 3.3%, 95% CI: −3.5, 10.5) had a big change as 
compared with 2003–2006 (APC = 34.0%, 95% CI: 9.7, 63.7), but 
a significant rise in the pace was also observed in general with an 
APC of 11.1%. Our result was similar to a previous study, which 
observed a significant rising trend of ovarian cancer incidence 
during 1999–2006, while a drop happened during 2006–2010 for 
urban women, and a continuous rise was observed in rural women 
(6). In recent years, in spite of the combination of docetaxel, intra-
peritoneal cisplatin hyperthermic perfusion chemotherapy and 
hyperthermia to treat advanced ovarian cancer and could reduce 
the number of deaths (25); lack of early diagnosis is a main factor 
that leads to increasing mortality rates, which also makes ovarian 
cancer remaining the most important cause of gynecological can-
cer. During the past years, people living standard rise ceaselessly 
with the rapid economic growth and lifestyle have been greatly 
changed. The consumption of meat and fat has been tremendously 
increased, which is directly associated with risk of obesity, higher 
BMI and WC (26). Compared with 2002, rates of overweight 
and obesity raised 7.3 and 4.8% among Chinese residents aged 
more than 18 years in 2012 (27). A meta-analysis estimated that 
compared with women with a body mass index in the “healthy” 
range (BMI 18.5–24.9), the risk of epithelial ovarian cancer 
among obese (BMI of 30 or more) and overweight (BMI 25–29.9) 
women had 30 and 16% increased risk, respectively (28). With 
the social and economic development, mental activity is gradually 
FigUre 4 | The mortality time trends of ovarian cancer in Jiangsu, 2003–2012.
FigUre 3 | The incidence time trends of ovarian cancer in Jiangsu, 2003–2012.
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replacing physical activity lifestyle which becomes the main way 
of our daily life. In a meta-analysis study, compared with women 
who described to the least exercise in daily life, the overall risk of 
ovarian cancer was 20% declined among women with recreational 
physical in both case–control and cohort  studies (29).
The risk differences between urban and rural areas were also 
found in other counties. In Egypt, it was reported around two 
times higher incidence of ovarian cancer in urban areas compared 
with rural areas (30). A report in China showed the incidence of 
ovarian cancer in urban areas was 9.37/100,000 while in rural 
areas was 5.02/100,000, which was similar to our results (31). 
Given the fact that women in a specific area are genetically simi-
lar, therefore most of the risk differences could be explained by 
socioeconomic status, environment, and lifestyles.
The age-specific incidence was observed to rise with age, and 
reached its first peak at age of 60–64 years, and second peak among 
85− years old. The same tendency of ovarian cancer shared in 
some Chinese reports (24, 31). Influence of the hormonal factors 
7Teng et al. Ovarian Cancer Incidence and Mortality
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on the development of ovarian cancer might differ by different 
age group. In terms of etiology, ovarian cancer is not actually 
a hormonally related cancer; it is not under direct stimulatory 
effects of estrogen (30). Ovarian cancer development is more 
related to risk factor that causes chronic inflammation, related to 
“incessant ovulation” (32, 33). However, hormones may affect the 
development of ovarian cancer to some degree. A strong inverse 
relationship was observed between each live birth and ovarian 
cancer. Compared with nulliparae, the OR for ovarian cancer was 
0.43, 0.30, and 0.18 for women whose parity was 1–2, 3–5, and 
6–, respectively (34). This study also found menopausal status 
was associated with increased risk of disease (OR =  2.15, 95% 
CI 1.21, 3.83) (34). In addition, the combined oral contraceptive 
(OCs) conferred a protective crucial feature of epithelial ovarian 
cancer and was the most significant from a public health perspec-
tive (35). The lifelong number of menstrual cycle has been found 
to link with ovarian cancer, which suggested that ovulation is 
implicated and may subsequent cause ovarian carcinogenesis, 
but parity and OCs seems to play more important roles than that 
of other factors (36).
The limitations of our study should be acknowledged. First, 
the selected registries might not adequately represent the whole 
province especially in the beginning. Second, detail informa-
tion of cancer cases, such as cancer stage and histological type, 
was not obtained in most registries; hence, we were not able to 
further analyze crude rates among stage and histological type, etc. 
Third, not all cancer registries are the members of International 
Association of Cancer Registration (IACR), and data were not 
included in Cancer Incidence in Five Continents yet.
In summary, ovarian cancer incidence has been significantly 
increased in Jiangsu in recent years, which also reflect the situa-
tion in China. Although the incidence and mortality are relatively 
low, considering the huge population, health education, and 
promotion of ovarian cancer have become increasingly important 
with respect to the prevention of ovarian cancer in China.
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